journal
MENU ▼
Read by QxMD icon Read
search

Biology of Blood and Marrow Transplantation

journal
https://www.readbyqxmd.com/read/28528711/clinical-impact-of-colonization-with-multidrug-resistant-organisms-on-outcome-after-autologous-stem-cell-transplantation-a-retrospective-single-center-study
#1
Sebastian Scheich, Claudia Reinheimer, Christian Brandt, Thomas A Wichelhaus, Michael Hogardt, Volkhard A J Kempf, Uta Brunnberg, Christian Brandts, Olivier Ballo, Ivana von Metzler, Johanna Kessel, Hubert Serve, Björn Steffen
During the last years, a significant increase in infections caused by multidrug-resistant organisms (MDRO) has been noticed, resulting in an increase of mortality in all fields of healthcare. Hematological patients are particularly affected by MDRO infections due to disease- and therapy-related immunosuppression. To determine the impact of colonization with MDRO on overall survival, we retrospectively analyzed data from patients undergoing autologous hematopoietic stem cell transplantation at our institution...
May 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28527985/long-term-follow-up-and-impact-of-comorbidity-prior-to-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-relapsed-or-refractory-aml-lessons-learned-from-the-prospective-bridge-trial-clofarabine-salvage-therapy-prior-to-allogeneic-transplantation
#2
Jan Moritz Middeke, Regina Herbst, Stefani Parmentier, Gesine Bug, Mathias Hänel, Gernot Stuhler, Kerstin Schäfer-Eckart, Wolf Rösler, Stefan Klein, Wolfgang Bethge, Ulrich Bitz, Bozena Büttner, Holger Knoth, Nael Alakel, Markus Schaich, Anke Morgner, Michael Kramer, Katja Sockel, Malte von Bonin, Friedrich Stölzel, Uwe Platzbecker, Christoph Röllig, Christian Thiede, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig
In patients with relapsed or refractory (r/r) AML, allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is considered to be the only treatment providing long-term disease control. The BRIDGE trial studied the safety and efficacy of a clofarabine-based salvage therapy prior to HSCT in patients with r/r AML. Here, we report the long-term follow up of this Phase II, multi-center trial and exploratory analyses on the impact of comorbidity on outcome. Eighty-four patients with a median age of 61 years (range 40 - 75) were enrolled...
May 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28527984/personalized-prognostic-risk-score-for-long-term-survival-for-children-with-acute-leukemia-after-allogeneic-transplant
#3
Menachem Bitan, Kwang Woo Ahn, Heather R Millard, Michael A Pulsipher, Hisham Abdel-Azim, Jeffery J Auletta, Valerie Brown, Ka Wah Chan, Miguel Angel Diaz, Andrew Dietz, Marta González Vincent, Gregory Guilcher, Gregory A Hale, Robert J Hayashi, Amy Keating, Parinda Mehta, Kasiani Myers, Kristin Page, Tim Prestidge, Nirali N Shah, Angela R Smith, Ann Woolfrey, Elizabeth Thiel, Stella M Davies, Mary Eapen
We studied leukemia-free (LFS) and overall survival (OS) in children with acute myeloid (AML; n=790) and acute lymphoblastic leukemia (ALL; n=1096), transplanted between 2000 and 2010, who survived for at least 1 year in remission after related or unrelated donor transplantation. Analysis of patient-, disease- and transplantation characteristics and acute and chronic graft versus host disease (GVHD) were performed to identify factors with adverse effects on LFS and OS. These data were used to develop risk scores for survival...
May 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28522345/allogeneic-hematopoietic-cell-transplantation-for-older-patients-prognosis-determined-by-disease-risk-index
#4
Fiona He, Qing Cao, Aleksandr Lazaryan, Claudio Brunstein, Shernan Holtan, Erica Warlick, Celalettin Ustun, Brian McClune, Mukta Arora, Armin Rashidi, Craig Eckfeldt, Daniel J Weisdorf, Nelli Bejanyan
The treatment of elderly patients with advanced hematological malignancies has expanded to include reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT) as a potentially curative option. We studied the association between disease risk index (DRI) and clinical outcomes of 196 elderly patients (median age: 64.8 [60-75] years) with hematological malignancies receiving RIC alloHCT (2000-2014). Donors were adult related and unrelated (RD, URD; n = 100, 51.1%) or umbilical cord blood (UCB) (n = 96, 48...
May 15, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28522344/acquired-complement-regulatory-gene-mutations-and-hematopoietic-stem-cell-transplant-related-thrombotic-microangiopathy
#5
Gianluigi Ardissino, Stefania Salardi, Silvia Berra, Giacomo Colussi, Massimo Cugno, Marco Zecca, Fabio Giglio, Jacopo Peccatori, Elisa Diral, Francesca Tel, Alberto Clivio, Silvana Tedeschi
Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) is a severe complication whose pathophysiology is unknown. We describe 6 patients in which the disease was associated with complement regulatory gene abnormalities received from their respective donors. It is suggested that mutated and transplanted monocyte-derived cells are responsible for production of abnormal proteins, complement dysregulation and, ultimately, for the disease. This observation might have important drawbacks as far as HSCT-TMA pathophysiology and treatment are concerned...
May 15, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28506845/ex-vivo-mesenchymal-precursor-cell-expanded-cord-blood-transplantation-following-reduced-intensity-conditioning-regimens-improves-time-to-neutrophil-recovery
#6
Rohtesh S Mehta, Rima M Saliba, Kai Cao, Indreshpal Kaur, Katy Rezvani, Julianne Chen, Amanda Olson, Simrit Parmar, Nina Shah, David Marin, Amin Alousi, Chitra Hosing, Uday Popat, Partow Kebriaei, Richard Champlin, Marcos de Lima, Donna Skerrett, Elizabeth Burke, Elizabeth J Shpall, Betul Oran
We previously showed the safety of using cord blood (CB) expanded ex vivo in cocultures with allogeneic mesenchymal precursor cells (MPC) after myeloablative conditioning with faster recovery of neutrophils and platelets compared with historical controls. Herein, we report the transplant outcomes of 27 patients with hematologic cancers who received one CB unit ex vivo expanded with MPCs in addition to an unmanipulated CB (MPC group) after reduced intensity conditioning (RIC). The results in this group were compared with 51 historical controls who received two unmanipulated CB units (control group)...
May 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28502840/the-perfect-transplant
#7
Shernan G Holtan
No abstract text is available yet for this article.
May 11, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28501543/allogeneic-hematopoietic-stem-cell-transplantation-for-adolescents-and-young-adults-with-acute-myeloid-leukemia
#8
Daisuke Tomizawa, Shiro Tanaka, Tadakazu Kondo, Yoshiko Hashii, Yasuyuki Arai, Kazuko Kudo, Takashi Taga, Takahiro Fukuda, Hiroaki Goto, Jiro Inagaki, Katsuyoshi Koh, Kazuteru Ohashi, Yukiyasu Ozawa, Masami Inoue, Koji Kato, Junji Tanaka, Yoshiko Atsuta, Souichi Adachi, Hiroyuki Ishida
Few reports have focused on adolescent and young adult (AYAs) patients with acute myeloid leukemia (AML) treated with hematopoietic stem cell transplantation (HSCT). We performed a retrospective analysis based on data obtained from a Japanese nationwide registration database to compare HSCT outcomes in AYA patients with AML with those in children with AML. An analysis of the 2,973 patients with de novo AML who received allogeneic HSCT from 1990 to 2013 showed inferior 5-year overall survival (OS) (54% vs. 58%, P<0...
May 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28499938/allogeneic-stem-cell-transplantation-in-myelofibrosis
#9
REVIEW
Tania Jain, Ruben A Mesa, Jeanne M Palmer
Myeloproliferative neoplasm is a category in the World Health Organization classification of myeloid tumors. BCR-ABL1-negative MPN is a subcategory that includes primary myelofibrosis (MF), post-essential thrombocythemia MF, and post-polycythemia vera MF. These disorders are characterized by stem cell-derived clonal myeloproliferation. Clinically, these diseases present with anemia and splenomegaly, as well as significant constitutional symptoms, such as severe fatigue, symptoms associated with an enlarged spleen and liver, pruritus, fevers, night sweats, and bone pain...
May 9, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28499937/haploidentical-allogeneic-hematopoietic-cell-transplantation-for-multiple-myeloma-using-post-transplant-cyclophosphamide-gvhd-prophylaxis
#10
Luca Castagna, Alberto Mussetti, Raynier Devillier, Alida Dominietto, Magda Marcatti, Giuseppe Milone, Francesco Maura, Chiara de Philippis, Benedetto Bruno, Sabine Furst, Didier Blaise, Paolo Corradini, Vittorio Montefusco
Allogeneic Hematopoietic Cell Transplantation (allo-HCT) currently represents the only potentially curative therapy for patients affected by multiple myeloma (MM). Up to 30% of patients in western countries do not have a matched donor. Haploidentical HCT (haplo-HCT) may be an option, but currently, there is are available data regarding this treatment. We analyzed survival outcomes of 30 heavily pretreated MM patients who received haplo-HCT with post-transplant cyclophosphamide (PT-Cy) as graft-versus-host-disease (GVHD) prophylaxis...
May 9, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28499936/ucbt-without-antithymocyte-globulin-results-in-similar-survival-but-better-quality-of-life-compared-with-upbsct-for-the-treatment-of-acute-leukemia-a-retrospective-study-in-china
#11
J Tong, L Xuan, Y L Sun, D P Huang, H L Liu, C C Zheng, X Y Zhu, B L Tang, K D Song, X H Zhang, L Zhang, W Yao, D J Lin, Q F Liu, Z M Sun
While previous studies have demonstrated improved outcomes in umbilical cord blood transplantation (UCBT) by omitting antithymocyte globulin (ATG) in the conditioning regimen, this approach has not been comparatively studied in unrelated peripheral blood stem cell transplantation (UPBSCT). To compare the risks and benefits between UCBT without ATG and UPBSCT in patients with acute leukemia (AL). This was a multicenter retrospective study of 79 patients who underwent UCBT (myeloablative conditioning without ATG) and 96 patients who underwent UPBSCT (myeloablative conditioning with ATG)...
May 9, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28495643/humoral-immune-reconstitution-kinetics-following-allogeneic-hematopoietic-stem-cell-transplantation-in-children-a-maturation-block-of-igm-memory-b-cells-may-lead-to-impaired-antibody-immune-reconstitution
#12
Hisham Abdel-Azim, Amro Elshoury, Kris M Mahadeo, Robertson Parkman, Neena Kapoor
Although T cell immune reconstitution following allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been well studied, long-term B cell immune reconstitution remains less characterized. We evaluated humoral immune reconstitution among 71-pediatric allo-HSCT recipients. While tetanus toxoid (TT) antibody levels were normal at 1-year post allo-HSCT, anti-polysaccharide carbohydrate (PRP) antibodies remained persistently low for up to 5-years. While naive B cell counts normalized by 6-months, IgM memory B cell deficiency persisted for up to 2-years (P=0...
May 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28495642/feasibility-of-lenalidomide-therapy-for-persistent-chronic-lymphocytic-leukemia-after-allogeneic-transplantation
#13
Maria R Khouri, Elias J Jabbour, Alison M Gulbis, Francesco Turturro, Celina Ledesma, Martin Korbling, Barry I Samuels, Sairah Ahmed, Amin M Alousi, Stefan O Ciurea, David Marin, Krina K Patel, Uday R Popat, Carlos E Bueso-Ramos, Roland L Bassett, Issa F Khouri
In patients with chronic lymphocytic leukemia (CLL), persistence of disease after allogeneic stem cell transplantation (alloSCT) can result in poor outcomes. In an effort to improve these outcomes, patients with persistent CLL who were 90-100 days post alloSCT with no evidence of graft-versus-host-disease (GVHD) were randomized to receive lenalidomide or standard care (withdrawal of immunosuppression followed by donor lymphocyte infusion). Lenalidomide was initiated at 5 mg every other day and increased to 10 mg daily if tolerated in each patient...
May 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28495641/safety-and-efficacy-of-infliximab-therapy-in-the-setting-of-steroid-refractory-acute-graft-versus-host-disease
#14
Fevzi F Yalniz, Mehrdad Hefazi, Kristen McCollough, Mark R Litzow, William J Hogan, Robert Wolf, Hassan Alkhateeb, Ankit Kansagra, Moussab Damlaj, Mrinal M Patnaik
Acute graft versus host disease (aGVHD) is the leading cause of morbidity and mortality following allogenic hematopoietic cell transplantation (HCT). Corticosteroids are the first line treatment; however, less than half of the patients achieve durable remissions. Studies suggest that tumor necrosis factor alpha (TNF-α), a cytokine released from the bone marrow during conditioning, is involved in the pathogenesis of aGVHD. We retrospectively evaluated the outcome of anti-tumor necrosis factor alpha (TNF-α) therapy with infliximab in 35 patients with steroid refractory aGVHD (SR-aGVHD)...
May 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28495640/sources-of-hematopoietic-stem-and-progenitor-cells-and-methods-to-optimize-yields-for-clinical-cell-therapy
#15
REVIEW
Sandhya R Panch, James Szymanski, Bipin N Savani, David F Stroncek
Bone marrow (BM) aspirates, mobilized peripheral blood (PB) and umbilical cord blood (UCB) have developed as graft sources of hematopoietic stem and progenitor cells (HSPC) for stem cell transplantation and other cellular therapeutics. Individualized techniques are necessary to enhance graft HSPC yields and cell quality from each graft source. BM aspirates yield adequate CD34+cells but can result in relative delays in engraftment. Granulocyte-colony stimulating factor (G-CSF) primed bone marrow HSPC may facilitate faster engraftment while minimizing graft-versus-host disease (GVHD) in certain patient subsets...
May 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28483716/prophylactic-donor-lymphocyte-infusion-dli-followed-by-minimal-residual-disease-and-graft-versus-host-disease-guided-multiple-dlis-could-improve-outcomes-after-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-refractory-relapsed-acute-leukemia
#16
Chen-Hua Yan, Qi-Fa Liu, De-Pei Wu, Xi Zhang, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, He Huang, Hai Bai, Fen Huang, Xiao Ma, Xiao-Jun Huang
Patients with refractory/relapsed acute leukemia who have received allogeneic hematopoietic stem cell transplantation (allo-HSCT) are still at a high risk for relapse post-transplant. To investigate the impact of prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease (MRD)-test and graft-versus-host disease (GvHD) guided multiple DLIs to prevent relapse and improve survival in patients with refractory/relapsed acute leukemia who received allo-HSCT. A multicenter prospective study was designed...
May 5, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28479164/recommendations-for-screening-and-management-of-late-effects-in-scid-patients-after-allogenic-hematopoietic-cell-transplantation-hct-a-consensus-statement-from-the-second-pediatric-blood-and-marrow-transplant-consortium-international-conference-on-late-effects
#17
REVIEW
J Heimall, R H Buckley, J Puck, T A Fleisher, A R Gennery, E Haddad, B Neven, M Slatter, Roderick S, K S Baker, A C Dietz, C Duncan, L M Griffith, L Notarangelo, M A Pulsipher, M J Cowan
Severe Combined Immunodeficiency (SCID) is effectively treated with HCT with overall survival approaching 90% in contemporary reports. However, survivors are at risk for development of late complications due to the variable durability of high quality immune function, underlying genotype of SCID, comorbidities due to infections in the pre- and post- transplant period and use of conditioning pre-transplant. An international group of transplant experts was convened in 2016 to review the current knowledge of late effects seen in SCID patients following HCT, and develop recommendations for screening and monitoring for late effects...
May 4, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28478121/outcome-of-allogeneic-and-autologous-hematopoietic-cell-transplant-for-high-risk-peripheral-t-cell-lymphomas-ptcls-a-retrospective-analysis-from-a-chinese-center
#18
Haiwen Huang, Yibin Jiang, Qiangli Wang, Lingchuan Guo, Zhengming Jin, Zhengzheng Fu, Yue Han, Aining Sun, Wei Liu, Jia Ruan, Depei Wu
Peripheral T-cell lymphomas (PTCLs) often carry poor outcomes with conventional chemotherapy, and hematopoietic cell transplantation (HCT) can benefit patients with PTCL. We conducted a retrospective review of 67 patients with peripheral T-cell lymphoma who underwent autologous HCT (autoHCT, n=43, median age 40 years) or allogeneic HCT (alloHCT, n=24, median age 36.5 years) from 2004 to 2016. With a median follow-up of 27 months, 5-year PFS and OS of autoHCT patients were 49% and 57%, respectively. Among alloHCT recipients, the 5-year PFS and OS were 54% and 55%, respectively...
May 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28478120/predictive-value-of-clinical-findings-and-plasma-biomarkers-after-14-days-of-prednisone-treatment-for-acute-graft-versus-host-disease
#19
George B McDonald, Laura Tabellini, Barry E Storer, Paul J Martin, Richard L Lawler, Steven L Rosinski, H Gary Schoch, John A Hansen
We examined the hypothesis that plasma biomarkers and concomitant clinical findings after initial glucocorticoid therapy can accurately predict failure of graft-versus-host-disease treatment and mortality. We analyzed plasma samples and clinical data in 165 patients after 14 days of glucocorticoid therapy and used logistic regression and areas under receiver-operating characteristic curves (AUC) to evaluate associations with treatment failure and non-relapse mortality (NRM). Initial treatment of GVHD was unsuccessful in 49 patients (30%)...
May 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28476490/phase-i-ii-study-of-intravenous-plerixafor-added-to-a-mobilization-regimen-of-g-csf-in-lymphoma-patients-undergoing-autologous-stem-cell-collection
#20
Amanda Cashen, Michael Rettig, Feng Gao, Angela Smith, Camille Abboud, Keith Stockerl-Goldstein, Ravi Vij, Geoffrey Uy, Peter Westervelt, John DiPersio
Plerixafor, given subcutaneously with G-CSF, improves autologous stem cell collection in patients with lymphoma and multiple myeloma. Intravenous (IV) administration of plerixafor allows administration of plerixafor the same day as pheresis, and it may improve stem cell collection. The primary objectives of this Phase I/II study were to determine the maximum tolerated dose of IV plerixafor, and the efficacy of IV plerixafor + G-CSF to mobilize ≥ 2 x 10(6) CD34+ cells/kg from patients with lymphoma. In Phase I, 25 patients were treated with G-CSF + IV plerixafor at escalating doses; in Phase II, 36 patients were treated with G-CSF + plerixafor 0...
May 2, 2017: Biology of Blood and Marrow Transplantation
journal
journal
20050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"